| Original language | English (US) |
|---|---|
| Pages (from-to) | 2980-2982 |
| Number of pages | 3 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 32 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2021 |
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Society of Nephrology, Vol. 32, No. 12, 12.2021, p. 2980-2982.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Back to the future
T2 - The role of metabolic studies in therapeutic advances
AU - Milliner, Dawn S.
AU - Lieske, John C.
N1 - Funding Information: This work was supported by National Institutes of Health grant R21TR003174. Funding Information: This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant UC2DK126021. Funding Information: J.C. Lieske reports having consultancy agreements with Allena Pharmaceuticals, Alnylam Pharmaceuticals, American Board of Internal Medicine (ABIM), Dicerna Pharmaceuticals, Federation Bio, Novobiome Orfan, Oxidien, OxThera, Siemens, and Synlogic; serving as a scientific advisor for, or member of, ABIM, Kidney International, and the Oxalosis and Hyperoxaluria Foundation (OHF); receiving honoraria from ABIM and UpToDate; and receiving research funding from Allena Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, National Institute of Diabetes and Digestive and Kidney Diseases, Retrophin, Siemens, and Synlogic. D.S. Milliner reports having consultancy agreements with Allena Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, and Synlogic (all consulting fees paid directly to Mayo Clinic); receiving research funding from Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and OxThera (all research funding is provided to Mayo Clinic and not to the author personally); serving on the advisory committee for Alnylam Pharmaceuticals, on the data safety and monitoring committee for a clinical trial conducted by Dicerna Pharmaceuticals, on the data safety monitoring board for a clinical trial conducted by OxThera, and on the editorial board for Urolithiasis; having other interests in/relationships with Kidney Health Initiative (KHI) and OHF via ongoing work for a KHI-sponsored project; and with the OHF (a nonprofit, private foundation) via ongoing work, which includes some research funding, but no personal compensation; and receiving honoraria from Synlogic Medical Advisory Committee (personal honorarium).
PY - 2021/12
Y1 - 2021/12
UR - http://www.scopus.com/inward/record.url?scp=85120618771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120618771&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021101325
DO - 10.1681/ASN.2021101325
M3 - Editorial
C2 - 36734820
AN - SCOPUS:85120618771
SN - 1046-6673
VL - 32
SP - 2980
EP - 2982
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 12
ER -